Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002028506 | SCV002283652 | uncertain significance | Familial cancer of breast | 2021-02-03 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with breast cancer (PMID: 28715532). This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 10 of the BARD1 gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. |
Myriad Genetics, |
RCV002028506 | SCV004044165 | likely pathogenic | Familial cancer of breast | 2023-05-25 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. |
Ce |
RCV003434380 | SCV004151313 | uncertain significance | not provided | 2023-09-01 | criteria provided, single submitter | clinical testing | BARD1: PM2 |
Baylor Genetics | RCV002028506 | SCV005054619 | uncertain significance | Familial cancer of breast | 2024-01-17 | criteria provided, single submitter | clinical testing |